Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0048 • ACR Convergence 2020
Determinants of Participation in Clinical Trials Among Patients with Lupus in the United States
Onengiya Harry¹, Carl Langefeld², Miranda Marion³, Trent Younts³, Lori Crosby⁴, Mara Vitolins³ and Avani Modi⁴, ¹Wake Forest School of Medicine, Clemmons, NC, ²Wake Forest School of Medicine, Winston Salem, NC, ³Wake Forest School of Medicine, Winston-Salem, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati
Background/Purpose: Patient and family participation in research is critical to improving health outcomes, and identifying factors that contribute to participation or lack of participation in…
Abstract Number: 0256 • ACR Convergence 2020
Patient Perspective of the Type 1 and 2 SLE Model: A Qualitative Study
Amanda Eudy¹, Amy Corneli², Kevin McKenna², Mithu Maheswaranathan¹, Bryce Reeve², David Pisetsky³ and Megan Clowse⁴, ¹Duke University, Durham, NC, ²Duke University, Durham, ³Duke University Medical Center, Durham, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: To better characterize the signs and symptoms of systemic lupus erythematosus (SLE) we have developed a conceptual model to characterize SLE activity into two dimensions: Type 1…
Abstract Number: 0273 • ACR Convergence 2020
Lupus Nephritis Is Associated with a Reduced Prevalence of Fibromyalgia
Jennifer Rogers¹, Megan Clowse², Lisa Criscione-Schreiber³, Jayanth Doss⁴, Rebecca Sadun⁴, Kai Sun⁵ and Amanda Eudy⁴, ¹Duke, Durham, NC, ²Duke University, Chapel Hill, NC, ³Duke University School of Medicine, Durham, NC, ⁴Duke University, Durham, NC, ⁵Duke University Hospital, Durham
Background/Purpose: Patients with SLE have poor health related quality of life (HRQoL), however the differences in the predominant causes of decreased HRQoL across subgroups of…
Abstract Number: 0291 • ACR Convergence 2020
SLAMF7 and CD38 on NK Cells Represent Potential New Therapeutic Targets for Systemic Lupus Erythematosus
Morgane Humbel¹, Florence Bellanger², Craig Fenwick², Alice Horisberger², Camillo Ribi² and Denis Comte², ¹CHUV, Lausanne, Vaud, Switzerland, ²CHUV, Lausanne, Switzerland
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by the production of autoantibodies. For this reason, anti-B cell therapy seems to be…
Abstract Number: 0433 • ACR Convergence 2020
Racial Disparities and New SLE-Specific Predictors of Stroke and Ischemic Heart Disease in Patients with Lupus
Shivani Garg¹, Christie Bartels², Gaobin Bao³, Cristina Drenkard⁴ and S. Sam Lim³, ¹UW Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI, ³Emory University, Atlanta, GA, ⁴Division of Rheumatology, Department of Medicine, Emory School of Medicine, Atlanta, GA
Background/Purpose: In the US, cardiovascular disease (CVD) is the leading cause of disparities in life expectancy between black and white populations. We recently reported a…
Abstract Number: 0570 • ACR Convergence 2020
The Patient Perspective on Using Digital Resources to Address Unmet Needs in Systemic Lupus Erythematosus
Jennifer Ra¹, Jerik Leung², Elizabeth Baker² and Alfred Kim¹, ¹Washington University School of Medicine, St. Louis, MO, ²Saint Louis University, College for Public Health and Social Justice, St. Louis
Background/Purpose: The clinical variability of systemic lupus erythematosus (SLE) caused by the unpredictability of flares contributes to patients experiencing a diminished sense of social support.…
Abstract Number: 0837 • ACR Convergence 2020
Deletion of miR-223 Exacerbates Lupus Nephritis by Targeting S1pr1 in Faslpr/lpr Mice
Sumie Hiramatsu Asano¹, Tomoyuki Mukai², Yoshitaka Morita³ and Jun Wada⁴, ¹Kawasaki Medical School/Department of Rheumatology, Kurashiki city, Japan, ²Kawasaki Medical School, Kurashiki-shi, Okayama, Japan, ³Kawasaki Medical School/Department of Rheumatology, Kurashiki, Okayama, Japan, ⁴Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences., Okayama city, Japan
Background/Purpose: To identify new candidate genes regulated by micro RNAs (miRNAs) and involved in the pathogenesis of systemic lupus erythematosus (SLE), we integrated miRNA and…
Abstract Number: 0857 • ACR Convergence 2020
Agreement of Hydroxychloroquine Blood Levels Between a University and Commercial Laboratory
Michelle Petri¹, Jessica Li², Kelley Brady³, John Conklin⁴, Tyler O'Malley⁵ and Thierry Dervieux⁶, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD, ³Exagen Diagnostics, San Diego, CA, ⁴Exagen Inc., Vista, CA, ⁵Exagen, Inc, San Diego, CA, ⁶Prometheus Biosciences, Inc. (former employee of Exagen Diagnostics), Irvine, CA
Background/Purpose: Therapeutic blood monitoring is not yet an accepted practice in rheumatology. Although hydroxychloroquine (HCQ) blood level monitoring has been utilized in limited pharmacokinetic studies…
Abstract Number: 0936 • ACR Convergence 2020
Urine Proteomics and Single Cell Transcriptomics Identify IL-16 as a Biomarker for Lupus Nephritis
Andrea Fava¹, Jill Buyon², Chandra Mohan³, Ting Zhang³, H. Michael Belmont⁴, Peter Izmirly⁵, Robert Clancy⁶, Jose Monroy-Trujillo⁷, Celine Berthier⁸, Anne Davidson⁹, Nir Hacohen¹⁰, David Wofsy¹¹, Deepak Rao¹², Soumya Raychaudhuri¹³, The Accelerating Medicines Partnership in SLE Network¹⁴, William Apruzzese¹⁵ and Michelle Petri¹⁶, ¹Johns Hopkins University, Baltimore, MD, ²Department of Medicine, NYU School of Medicine, New York, NY, ³UT Houston, Houston, ⁴New York University, New York, NY, ⁵Department of Medicine, New York University School of Medicine, New York, NY, ⁶NYU School of Medicine, New York, ⁷Johns Hopkins University, Baltimore, ⁸University of Michigan, Ann Arbor, ⁹Northwell Health, New York, ¹⁰Broad Institute, Boston, ¹¹University of California San Francisco, San Francisco, CA, ¹²Brigham and Women's Hospital, Boston, MA, ¹³Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹⁴Multiple Institutions, Multiple Cities, ¹⁵., Boston, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Treatment of lupus nephritis relies on renal histopathological features. However, renal biopsies do not capture patient-specific active biological pathways. Urine proteomic biomarkers could revolutionize…
Abstract Number: 1017 • ACR Convergence 2020
Racial and Ethnic Disparities in the Risk of Preterm Birth Among Women with Systemic Lupus Erythematosus or Rheumatoid Arthritis with Varying Reference Groups
Lena Sabih¹, Jennifer Strouse¹, Gretchen Bandoli², Rebecca Baer³, Laura Jelliffe-Pawlowski³, Christina Chambers², Namrata Singh⁴ and Kelli Ryckman⁵, ¹University of Iowa Hospitals and Clinics, Iowa City, IA, ²University of California San Diego, La Jolla, CA, ³University of California San Francisco, San Francisco, ⁴University of Washington, Bellevue, WA, ⁵University of Iowa, Iowa City
Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are independently associated with preterm birth (PTB). Black women have higher risk of both ARD and…
Abstract Number: 1146 • ACR Convergence 2020
Pilot Study of an Internet-Based Pain Coping Skills Training Program for Patients with Systemic Lupus Erythematosus
Kelli Allen¹, Tyler Beuchamp², Rebecca Cleveland³, Kimberlea Grimm¹, David Hu¹, Katie Huffman¹, Frances Keefe⁴, Julie Norfleet¹, Christine Rini⁵, Andres Santana¹, Shruti Saxena Beem⁶ and Saira Sheikh⁷, ¹University of North Carolina at Chapel Hill, Chapel HIll, NC, ²Medical College of Georgia, Augusta, GA, ³University of North Carolina, Chapel Hill, NC, ⁴Duke University Medical Center, Durham, NC, ⁵Northwestern University, Chicago, IL, ⁶University of North Carolina at Chapel Hill, Chapel Hill, ⁷University of North Carolina Thurston Arthritis Research Center, Chapel Hill
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) have increased symptoms of fatigue, chronic pain, depression and anxiety, which are associated with negative impacts on quality…
Abstract Number: 1272 • ACR Convergence 2020
Impact of Remission and Low Disease Activity Status on Hospitalizations Among SLE Patients from the GLADEL Latin American Cohort
Guillermo Pons-Estel¹, Manuel Ugarte-Gil², Guillermina Harvey³, Daniel Wojdyla⁴, Rosana Quintana¹, Rosa Serrano-Morales¹, José Gómez-Puerta⁵, Mercedes García⁶, Luis Catoggio⁷, Verónica Saurit⁸, Cristina Drenkard⁹, Nilzio Antonio Da Silva¹⁰, Fernando Cavalcanti¹¹, Eduardo Borba¹², Emilia Sato¹³, Oscar Neira¹⁴, Loreto Massardo¹⁵, Gloria Vásquez¹⁶, Luis Alonso Gonzalez¹⁷, Marlene Guibert Toledan¹⁸, Luis Silveira¹⁹, Ignacio García De La Torre²⁰, María Josefina Sauza del Pozo²¹, Rosa Chacón²², Mario Cardiel²³, Graciela Alarcón²⁴ and Bernardo Pons-Estel²⁵, ¹Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ²Servicio de Reumatología. Hospital Nacional Guillermo Almenara Irigoyen and Universidad Científica del Sur, Lima, Peru, ³Guillermina Escuela de Estadística, Facultad de Ciencias Económicas y Estadística, Universidad Nacional de Rosario, Rosario, Argentina, ⁴GLADEL consultant, Rosario, Argentina, ⁵Servicio de Reumatología, Hospital Clinic., Barcelona, Spain, ⁶Servicio de Reumatología del HIGA San Martin de La Plata, La Plata, Argentina, ⁷Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸Servicio de Reumatología, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ⁹Division of Rheumatology, Department of Medicine, Emory School of Medicine, Atlanta, GA, ¹⁰Reumatologia/Departamento de Clínica Médica, Hospital das Clínicas, Universidade Federal de Goiás, Goias, Brazil, ¹¹Serviço de Reumatologia, Departamento de Medicina Clínica, Centro de Ciências Médicas, Hospital das Clínicas, Universidade Federal de Pernambuco, Pernambuco, Brazil, ¹²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ¹³Escola Paulista de Medicina, Universidad Federal São Paulo, São Paulo, Brazil, ¹⁴Sección de Reumatología, Hospital del Salvador, Universidad de Chile, Santiago, Chile, ¹⁵Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile, ¹⁶Grupo de Inmunología Celular e Inmunogenética, Facultad de Medicina, Universidad de Antioquía, Medellín, Colombia, ¹⁷Sección de Reumatología, Departamento de Medicina Interna, Universidad de Antioquía, Medellín, Colombia, ¹⁸Marlene Centro de Investigaciones Médicas Quirúrgicas, Havana, Cuba, ¹⁹Departamento de Inmunología / Departamento de Reumatología, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, ²⁰Departamento de Inmunología y Reumatología, Hospital General de Occidente de la S.S. y Universidad de Guadalajara, Jalisco, Mexico, ²¹Instituto Mexicano de Seguro Social, Hospital de Especialidades Nº 25, Monterrey, Mexico, ²²Servicio de Reumatología, Policlínica Méndez Gimón, Caracas, Venezuela, ²³Centro de Investigación Clínica de Morelia, Morelia, Mexico, ²⁴Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama at Birmingham; Department of Medicine, School of Medicine; Universidad Peruana Cayetano, Heredia, Alabama, ²⁵Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina
Background/Purpose: To determine whether remission and low disease activity state (LDAS) reduce hospitalizations in systemic lupus erythematosus (SLE) patients.Methods: A multi-ethnic, multi-national Latin-American SLE cohort…
Abstract Number: 1288 • ACR Convergence 2020
Predictors of Frailty Identified by the Short Physical Performance Battery and Associations with Patient-reported Outcomes
Patricia Katz¹, Jinoos Yazdany², Laura Trupin³, Stephanie Rush², Cristina Lanata³, Lindsey Criswell⁴ and Maria Dall'Era⁵, ¹University of California, San Francisco, Novato, CA, ²University of California, San Francisco, San Francisco, CA, ³UCSF, San Francisco, CA, ⁴Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA, ⁵Division of Rheumatology, University of California, San Francisco, CA
Background/Purpose: Frailty, defined as a generalized vulnerability to stressors, has emerged as a relevant concept in SLE1, although its origins are in geriatrics. As defined…
Abstract Number: 1441 • ACR Convergence 2020
Effects of Belimumab on Renal Outcomes, Overall SLE Control and Biomarkers: Findings from a Phase 3, Randomized, Placebo-controlled 104-week Study in Patients with Active Lupus Nephritis
Richard Furie¹, Brad Rovin², Frédéric Houssiau³, Gabriel Contreras⁴, Ana Malvar⁵, Amit Saxena⁶, Xueqing Yu⁷, Y K Onno Teng⁸, Pieter van Paassen⁹, Ellen M Ginzler¹⁰, Diane Kamen¹¹, Mary Oldham¹², Damon Bass¹³, Andre van Maurik¹⁴, Mary Beth Welch¹³, Yulia Green¹⁵, Beulah Ji¹⁵, Christi Kleoudis¹⁶ and David Roth¹⁷, ¹Northwell Health, Great Neck, NY, ²The Ohio State University, Columbus, ³Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁴University of Miami Miller School of Medicine, Miami, ⁵Organizacion Medica de Investigacion, Buenos Aires, Argentina, ⁶NYU School of Medicine, New York, ⁷Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China (People's Republic), ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹Maastricht University, Academisch Ziekenhuis Maastricht, Maastricht, Netherlands, ¹⁰SUNY Downstate Health Sciences University, Brooklyn, ¹¹Medical University of South Carolina, Charleston, SC, ¹²GlaxoSmithKline, Stevenage, United Kingdom, ¹³GlaxoSmithKline, Research Triangle Park, ¹⁴GlaxoSmithKline, Stevenage, ¹⁵GlaxoSmithKline, Uxbridge, ¹⁶Parexel (*At the time of study), Durham, ¹⁷GlaxoSmithKline, Collegeville
Background/Purpose: Belimumab (BEL) has demonstrated efficacy in systemic lupus erythematosus (SLE) in 4 positive pivotal trials. This study assessed the efficacy and safety of intravenous…
Abstract Number: 1515 • ACR Convergence 2020
Renal Responder Status and Associated Clinical Variables in the Lupus Accelerating Medicines Partnership Cohort
Philip Carlucci¹, Andrea Fava², Kristina Deonaraine¹, Jessica Li³, David Wofsy⁴, Judith James⁵, Chaim Putterman⁶, Betty Diamond⁷, Derek Fine⁸, Jose Monroy-Trujillo⁸, Kristin Haag⁸, William Apruzzese⁹, H. Michael Belmont¹⁰, Peter Izmirly¹¹, Sean Connery¹², Fernanda Payan-Schober¹², Richard Furie¹³, Celine Berthier¹⁴, Maria Dall'Era¹⁵, Kerry Cho¹⁶, Diane Kamen¹⁷, Kenneth Kalunian¹⁸, The Accelerating Medicines Partnership in SLE Network¹⁹, Michelle Petri²⁰ and Jill Buyon²¹, ¹New York University School of Medicine, New York, ²Johns Hopkins, Baltimore, ³Johns Hopkins University, Baltimore, MD, ⁴University of California San Francisco, San Francisco, CA, ⁵Oklahoma Medical Research Foundation, Oklahoma City, ⁶Albert Einstein College of Medicine, Bronx, NY, ⁷Northwell Health, Hartford, ⁸Johns Hopkins University, Baltimore, ⁹., Boston, ¹⁰NYU School of Medicine, New York, NY, ¹¹Department of Medicine, New York University School of Medicine, New York, NY, ¹²Texas Tech University Health Sciences Center, Lubbock, ¹³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ¹⁴University of Michigan, Ann Arbor, ¹⁵Division of Rheumatology, University of California, San Francisco, CA, ¹⁶University of California San Francisco, San Francisco, ¹⁷Medical University of South Carolina, Charleston, SC, ¹⁸School of Health Sciences, University of California, La Jolla, ¹⁹Multiple Institutions, Multiple Cities, ²⁰Johns Hopkins University School of Medicine, Baltimore, ²¹Department of Medicine, NYU School of Medicine, New York, NY
Background/Purpose: Poor therapeutic response rates contribute to the increased morbidity and mortality associated with lupus nephritis. Early identification of patients likely to respond is crucial…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].